Logo image of ARGX.BR

ARGENX SE (ARGX.BR) Stock Price, Quote, News and Overview

EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR

555.4  -22.8 (-3.94%)

ARGX.BR Quote, Performance and Key Statistics

ARGENX SE

EBR:ARGX (3/7/2025, 7:00:00 PM)

555.4

-22.8 (-3.94%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High658
52 Week Low322.5
Market Cap33.75B
Shares60.76M
Float60.68M
Yearly DividendN/A
Dividend YieldN/A
PE253.61
Fwd PE56.79
Earnings (Next)05-08 2025-05-08/bmo
IPO07-10 2014-07-10


ARGX.BR short term performance overview.The bars show the price performance of ARGX.BR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

ARGX.BR long term performance overview.The bars show the price performance of ARGX.BR in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80

The current stock price of ARGX.BR is 555.4 EUR. In the past month the price decreased by -12.12%. In the past year, price increased by 55.62%.

ARGENX SE / ARGX Daily stock chart

ARGX.BR Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B
1MRNA.MI MODERNA INC N/A 12.34B

About ARGX.BR

Company Profile

ARGX logo image argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland and currently employs 1,148 full-time employees. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Company Info

ARGENX SE

Laarderhoogtweg 25

Amsterdam NOORD-HOLLAND NL

Employees: 1148

Company Website: https://www.argenx.com/

Investor Relations: https://www.argenx.com/investors

Phone: 31763030

ARGENX SE / ARGX.BR FAQ

What is the stock price of ARGENX SE today?

The current stock price of ARGX.BR is 555.4 EUR. The price decreased by -3.94% in the last trading session.


What is the ticker symbol for ARGENX SE stock?

The exchange symbol of ARGENX SE is ARGX and it is listed on the Euronext Brussels exchange.


On which exchange is ARGX.BR stock listed?

ARGX.BR stock is listed on the Euronext Brussels exchange.


What is the price forecast or stock price prediction for ARGENX SE stock?

25 analysts have analysed ARGX.BR and the average price target is 658.04 EUR. This implies a price increase of 18.48% is expected in the next year compared to the current price of 555.4. Check the ARGENX SE stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARGENX SE worth?

ARGENX SE (ARGX.BR) has a market capitalization of 33.75B EUR. This makes ARGX.BR a Large Cap stock.


How many employees does ARGENX SE have?

ARGENX SE (ARGX.BR) currently has 1148 employees.


What are the support and resistance levels for ARGENX SE (ARGX.BR) stock?

ARGENX SE (ARGX.BR) has a support level at 334 and a resistance level at 559.79. Check the full technical report for a detailed analysis of ARGX.BR support and resistance levels.


Is ARGENX SE (ARGX.BR) expected to grow?

The Revenue of ARGENX SE (ARGX.BR) is expected to grow by 60.95% in the next year. Check the estimates tab for more information on the ARGX.BR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ARGENX SE (ARGX.BR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARGENX SE (ARGX.BR) stock pay dividends?

ARGX.BR does not pay a dividend.


When does ARGENX SE (ARGX.BR) report earnings?

ARGENX SE (ARGX.BR) will report earnings on 2025-05-08, before the market open.


What is the Price/Earnings (PE) ratio of ARGENX SE (ARGX.BR)?

The PE ratio for ARGENX SE (ARGX.BR) is 253.61. This is based on the reported non-GAAP earnings per share of 2.19 and the current share price of 555.4 EUR. Check the full fundamental report for a full analysis of the valuation metrics for ARGX.BR.


ARGX.BR Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ARGX.BR. When comparing the yearly performance of all stocks, ARGX.BR is one of the better performing stocks in the market, outperforming 91.68% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ARGX.BR Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ARGX.BR. ARGX.BR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARGX.BR Financial Highlights

Over the last trailing twelve months ARGX.BR reported a non-GAAP Earnings per Share(EPS) of 2.19. The EPS increased by 146.3% compared to the year before.


Industry RankSector Rank
PM (TTM) 38.03%
ROA 17.37%
ROE 19.54%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%194.05%
Sales Q2Q%82.18%
EPS 1Y (TTM)146.3%
Revenue 1Y (TTM)23.38%

ARGX.BR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to ARGX.BR. The Buy consensus is the average rating of analysts ratings from 25 analysts.

For the next year, analysts expect an EPS growth of 346.1% and a revenue growth 60.95% for ARGX.BR


Ownership
Inst Owners39.35%
Ins Owners0.12%
Short Float %N/A
Short RatioN/A
Analysts
Analysts78.4
Price Target658.04 (18.48%)
EPS Next Y346.1%
Revenue Next Year60.95%